App-based self-management of urgency and mixed urinary incontinence in women: One-year follow-up.
eHealth
long-term follow-up
mHealth
mixed urinary incontinence
mobile app
telehealth
treatment
urgency urinary incontinence
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
22
01
2022
received:
28
09
2021
accepted:
11
02
2022
pubmed:
11
3
2022
medline:
30
4
2022
entrez:
10
3
2022
Statut:
ppublish
Résumé
To evaluate the long-term effect of the Tät®II app for treatment of urgency (UUI) and mixed urinary incontinence (MUI). Long-term follow-up of a randomized controlled trial, including 123 women ≥18 years old with UUI or MUI, without red-flag symptoms, and ≥2 leakages per week. All participants, regardless of group, had received the intervention, a treatment app, at the long-term follow-up. Long-term data were collected through web-based questionnaires 15 months after participants received the intervention. The app included pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, an exercise log, reminders, reinforcement messages, and tailored advice. The primary outcome was a change in incontinence symptoms (International Consultation on Incontinence Questionnaire [ICIQ]-Urinary Incontinence Short Form [ICIQ-UI SF]), from baseline to follow-up. Other outcomes were urgency symptoms (ICIQ-Overactive Bladder Module (ICIQ-OAB)), quality of life (ICIQ-Lower Urinary Tract Symptoms Quality of Life Module [ICIQ-LUTSqol]), and improvement (Patient's Global Impression of Improvement [PGI-I]). Of the 123 women, 102 (83%) completed the long-term follow-up. The ICIQ-UI SF mean score improved from 11.5 to 7.6 (mean difference 4.0, 95% CI 3.2-4.7). The ICIQ-OAB improved from 6.7 to 5.5 (mean difference 1.3, 95% CI 0.9-1.6) and the ICIQ-LUTSqol improved from 38.0 to 30.9 (mean difference 7.1, 95% CI 5.7-8.5). Of the 102 women, 74 (73%) reported improvement. Self-management with the Tät®II app for UUI and MUI had a significant effect across all outcome measures also long-term and might serve as an alternative first-line treatment for these conditions.
Identifiants
pubmed: 35266189
doi: 10.1002/nau.24898
pmc: PMC9313824
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-954Informations de copyright
© 2022 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC.
Références
J Med Internet Res. 2016 May 16;18(5):e97
pubmed: 27185295
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781
pubmed: 17054185
J Med Internet Res. 2021 Apr 5;23(4):e19439
pubmed: 33818395
Neurourol Urodyn. 2022 Apr;41(4):945-954
pubmed: 35266189
Neurourol Urodyn. 2015 Nov;34(8):747-51
pubmed: 25154378
JAMA. 2017 Oct 24;318(16):1592-1604
pubmed: 29067433
BJU Int. 2003 Nov;92(7):731-5
pubmed: 14616456
Acta Obstet Gynecol Scand. 2017 Oct;96(10):1180-1187
pubmed: 28718223
J Clin Epidemiol. 2000 Nov;53(11):1150-7
pubmed: 11106889
Am J Obstet Gynecol. 2003 Jul;189(1):98-101
pubmed: 12861145
Phys Ther. 2010 Oct;90(10):1493-505
pubmed: 20671098
Neurourol Urodyn. 2009;28(5):411-5
pubmed: 19214996
J Urol. 2006 Mar;175(3 Pt 1):1063-6; discussion 1066
pubmed: 16469618
Health Technol Assess. 2020 Dec;24(70):1-144
pubmed: 33289476
BJU Int. 2015 Dec;116(6):955-64
pubmed: 25683075
Int Urogynecol J. 2020 Jun;31(6):1163-1174
pubmed: 31267139
Int J Clin Pract. 2011 Jun;65(6):705-12
pubmed: 21564445
BJOG. 2022 Aug;129(9):1474-1480
pubmed: 34437756
Neurourol Urodyn. 2013 Mar;32(3):215-23
pubmed: 22847318
Int Urogynecol J. 2010 Jan;21(1):5-26
pubmed: 19937315
Eur Urol. 2020 Dec;78(6):786-811
pubmed: 32616405